Smith L J, Maloy W L, Braylan R C, Wakeland E K
Cancer Res. 1985 Dec;45(12 Pt 1):6119-23.
Three peptides homologous to each heavy chain hypervariable region expressed by murine B-cell leukemia, BCL1, were synthesized in vitro by solid phase peptide synthesis. All three synthetic peptides elicited responses in rabbits which were immunized with synthetic peptide or synthetic peptide conjugated to the carrier keyhole limpet hemocyanin. Six individual rabbits were immunized, five of which responded by producing antisera which react specifically in radioimmunoassay with the synthetic peptide used as immunogen. One antiserum has specificity for the peptide homologous to the first hypervariable region, three antisera have specificity for the peptide homologous to the second hypervariable region, and one has specificity for the peptide homologous to the third hypervariable region. The five antisera with high titers of antibody recognizing synthetic peptide also specifically recognize native immunoglobulin M secreted by BCL1 tumor cells as demonstrated by immunoprecipitation followed by sodium dodecyl sulfate: polyacrylamide gel electrophoresis and autoradiography. These five antisera do not show reactivity with immunoglobulin secreted by spleen cells from normal BALB/cAn mice or by B-cells from unrelated tumors and cell lines. However, as determined by absorption experiments, the majority of antibodies in each antiserum are directed against the respective synthetic peptide, and only a small portion are reactive with native immunoglobulin M. Nonetheless, these results indicate use of synthetic peptides as a potential alternative source of immunogen for production of antitumor antibody.
通过固相肽合成法在体外合成了与小鼠B细胞白血病BCL1表达的每条重链高变区同源的三种肽。用合成肽或与载体钥孔血蓝蛋白偶联的合成肽免疫兔子时,所有这三种合成肽都能引发反应。对六只兔子进行了免疫,其中五只产生了抗血清,这些抗血清在放射免疫分析中能与用作免疫原的合成肽发生特异性反应。一种抗血清对与第一个高变区同源的肽具有特异性,三种抗血清对与第二个高变区同源的肽具有特异性,一种对与第三个高变区同源的肽具有特异性。通过免疫沉淀,随后进行十二烷基硫酸钠:聚丙烯酰胺凝胶电泳和放射自显影,证实了这五种具有高滴度识别合成肽抗体的抗血清也能特异性识别BCL1肿瘤细胞分泌的天然免疫球蛋白M。这五种抗血清与正常BALB/cAn小鼠脾细胞或无关肿瘤及细胞系的B细胞分泌的免疫球蛋白无反应。然而,通过吸收实验确定,每种抗血清中的大多数抗体都针对各自的合成肽,只有一小部分与天然免疫球蛋白M有反应。尽管如此,这些结果表明合成肽可作为生产抗肿瘤抗体的潜在替代免疫原来源。